Dr. Samuel M. Kim
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 5,701
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: Harvard Medical School
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
NY license 288447 -
Nuclear Cardiology Physician
NY license 288447
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- New York-Presbyterian Hospital New York, NY
- North Shore University Hospital Manhasset, NY
- Mount Sinai Hospital New York, NY
- Hospital for Special Surgery New York, NY
Medical groups
- Weill Medical College of Cornell (2,051 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 5,701
- Services billed
- 12,519
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 4,777 | 2,338 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 826 | 804 |
| Established patient office or other outpatient visit, 30-39 minutes | 292 | 230 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 150 | 149 |
| Injection, regadenoson, 0.1 mg | 148 | 37 |
| Critical care, first 30-74 minutes | 144 | 58 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 138 | 70 |
| Insertion of needle into vein for collection of blood sample | 114 | 100 |
| Ultrasound of both sides of head and neck blood flow | 75 | 75 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 70 | 70 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Atorvastatin Calcium Other prescribers in New York, NY | 162 |
| Metoprolol Succinate Other prescribers in New York, NY | 127 |
| Repatha Sureclick (evolocumab) Other prescribers in New York, NY | 120 |
| Ezetimibe Other prescribers in New York, NY | 96 |
| Rosuvastatin Calcium Other prescribers in New York, NY | 88 |
| Amlodipine Besylate Other prescribers in New York, NY | 85 |
| Eliquis (apixaban) Other prescribers in New York, NY | 78 |
| Praluent Pen (alirocumab) Other prescribers in New York, NY | 57 |
| Lisinopril Other prescribers in New York, NY | 39 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in New York, NY | 38 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $52.11 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $26.41 |
|---|---|
| Merck Sharp & Dohme LLC | $25.70 |
| Food and Beverage | $26.41 |
|---|---|
| Education | $25.70 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Dec 3, 2025 | Education in-kind | $25.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $110,449 in research payments for these studies, mostly to the institutions running them.
- A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS]
Novartis Pharmaceuticals Corporation - Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Novartis Pharmaceuticals Corporation - A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Dis…
Novartis Pharmaceuticals Corporation - A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
Eli Lilly and Company · Recruiting · NCT07269210
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.